Scientists showed the application of CRISPR/Cas9 to achieve >90% CCR5 editing in human, mobilized hematopoietic stem progenitor cells, resulting in a transplant that underwent normal hematopoiesis, produced CCR5 null T cells, and rendered xenograft mice refractory to HIV infection.
[Nature Communications]
